Recent advances in molecular biology, immunology, and peptide synthesis provide a basis for producing virtually unlimited quantities of purified viral proteins and small synthetic viral peptides for use in immunoprophylaxis. Success of this approach will not be limited by technologic constraints but rather by the poor antigenicity of purified antigens and synthetic peptides and the need for potent, acceptable adjuvants not now available. If the problem of poor antigenicity can be solved, nonreplicating antigens should prove satisfactory for use in prevention of viral diseases in which systemic spread plays an important role in pathogenesis.
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However, I am less sanguine about the prospects for using nonreplicating antigen vaccines to prevent viral diseases limited primarily to mucosal surfaces. My thoughts about immunoprophylaxis against viral infections that affect primarily mucosal surfaces are heavily influenced by the important role played by local immunity in resistance to most respiratory and gastrointestinal pathogens. Also, cytotoxic T cells have recently been shown to play an important role in recovery from influenza virus infection. Infection of the respiratory or gastrointestinal tract induces systemic immunoglobulin and cell-mediated immunity as well as local immunity and thus all phases of host defense are brought into play. In contrast, inactivated antigens are less effective in stimulating local immunity and cytotoxic T-cell response. For these reasons efforts to develop attenuated mutants for use in immunization should continue.
LIVE ATTENUATED VIRAL VACCINES The first vaccine used in man contained live vaccinia virus developed by Jenner almost 200 years ago for the control of smallpox. During the ensuing two centuries, vaccinia virus has had a noble record of success in controlling this disease in many parts of the world. Vaccinia virus also played an essential role in the final eradication of smallpox.
It is ironic that the origin of this most influential of vaccine virus strains remains obscure. Attempts to determine the origin of vaccinia using modern molecular biologic techniques have yielded equivocal results. Vaccinia virus is not identical to either variola virus or cowpox virus, but has features of both, suggesting that it may be a recombinant virus [1] .
Subsequent live attenuated viral vaccines have had a clearer lineage than vaccinia virus. Thus, each of the later vaccine viruses was derived from a wild-type human virus that was passaged serially in an unnatural host leading to the emergence of a host range mutant that was partially restricted in its growth in man. In this manner, monkey kidney cell culture was used to derive attenuated mutants of the polioviruses and rubella virus. Attenuated strains of yellow fever virus and measles virus were derived in the same way, using chick embryo cell culture. Finally, attenuated mumps virus was selected following serial cultivation in embryonated hens' eggs. In the case of measles virus, satisfactory attenuation required additional mutations that were selected for during growth at suboptimal temperature.
Attenuated host range mutants probably accumulate many mutations, making it difficult to define in a precise way the genetic basis of satisfactory attenuation. For example, the type 1 poliovirus vaccine strain is estimated to have undergone 35 base changes during its passage and plaque purification in monkey kidney cell culture [2] .
In some instances mutant phenotypes (laboratory markers) that correlate with attenuation have been identified, but their actual role in attenuation has not been established. Thus, the genetic basis of attenuation of live vaccine viruses now in use is not known. This is illustrated by the failure of Theiler and associates to produce additional attenuated mutants of yellow fever virus using the protocol that yielded the satisfactorily attenuated 17D strain of virus [3] .
It should be noted that live viral vaccines are not without their problems. The most serious of these difficulties is genetic instability that is typified by the emergence of virus with altered phenotype during the course of infection with vaccine virus. For example, virus with increased neurovirulence for monkeys is often shed by vaccinees infected with live attenuated poliovirus vaccine [4] . Genetic instability was also a problem with the live yellow fever virus vaccine during its early history when some batches of vaccine caused encephalitis [5] . It has been particularly difficult to address these problems without knowledge of the genetic basis of attenuation. NEW APPROACHES TO CONSTRUCTION OF ATTENUATED VIRUSES Influenza Viruses bearing specific, identifiable, attenuating mutations represent the live vaccine strains of the future because the genetic basis for attenuation is known and can be monitored directly during all phases of vaccine development, manufacture, and utilization in humans. The greatest success in producing and characterizing such attenuating mutations has been achieved with influenza A virus, whose segmented genome facilitates the segregation and characterization of individual genes.
Several groups have sought to produce mutant influenza genes that would confer a satisfactory level of attenuation upon any virus into which they were transferred by genetic reassortment. In studies performed by Murphy and associates, chemical mutagenesis was used to produce temperature-sensitive (ts) mutations on genes that code for nonsurface viral proteins so that the mutant genes could be transferred into reassortant viruses bearing the surface antigens of new epidemic or pandemic strains [6] . It is implicit in this approach that chemically induced ts mutations are primarily responsible for the attenuation of reassortant viruses bearing ts genes. This was shown to be the case for reassortants derived from two different ts donor viruses [6] .
Although the ts genes from one of these donor viruses, ts-1A2, conferred a satisfactory level of attenuation upon a series of reassortant Many of the influenza genes that have evolved over a long period of time in birds differ significantly from the corresponding genes of human influenza viruses when studied by nucleic acid hybridization [8] . Because of these marked differences, it is likely that the avian genes will retain their attenuated characteristics after limited replication in man, and thereby prove to be stable phenotypically. Deletion Mutants: Negative-Strand RNA Viruses Another approach to the construction of stable mutants involves deletion mutations that should be stable because they are not subject to reversion, and it is unlikely that they would be easily suppressed by a new mutation at another site on the viral genome. For these reasons we have initiated attempts to produce stable deletion mutations that will render a virus sufficiently defective so that it becomes attenuated, but not so defective that it loses viability. This type of genetic surgery can only be performed on DNA. Hence those viral genomes that are composed of RNA must be transcribed into DNA and then manipulated in this form. This presents us with the difficult problem of transcribing mutant DNA into an RNA form that can be transferred back into an infectious virus.
Before discussing strategy for producing stable deletion mutants for use in immunoprophylaxis, it should be noted that viable deletion mutants of several DNA animal viruses, including adenoviruses and papovaviruses, have been prepared, and some of these mutants exhibit a reduced capacity for viral replication in vitro and in vivo [9] [10] [11] . This is of interest because reduced replicative capacity is synonymous with attenuation.
The general plan for construction of deletion mutants of negative-strand RNA In the second phase of the plan, full-length cloned influenza DNA was used to produce influenza RNA in eukaryotic cells [13] . A late region deletion mutant of SV40 was used for construction of influenza DNA-SV40 hybrid molecules. The influenza DNA was inserted into the late region of the SV40 genome previously occupied by the deleted sequences that code for SV40 capsid proteins. The control of rotaviral infection in infancy and early childhood represents an important public health challenge since 50 percent or more of severe pediatric diarrheal disease in most parts of the world is caused by the rotaviruses [15] . It should be noted that diarrheal disease is the leading cause of mortality in infants and young children in developing countries. Efforts at immunoprophylaxis have been hampered by the fastidious nature of the human rotaviruses. Until recently, these viruses could not be grown serially to high titer in tissue culture. Fortunately, this obstacle was overcome during the past two years.
The first success in cultivation of human rotavirus was reported by Wyatt and his associates in our laboratory [16] . He identified a tissue culture-adapted mutant of the Wa strain of type 2 rotavirus that emerged during serial passage of this virus in a permissive animal host, the gnotobiotic piglet. The tissue culture-adapted mutant grew to high titer and was shown to be of human origin by polyacrylamide gel analysis of its RNA and by cross-neutralization studies.
Similar efforts to select a culture-adapted mutant of type 1 human rotavirus failed since this virus could not be passaged in piglets. For this reason, Greenberg and his associates developed another strategy which took into account the segmented viral genome of the rotaviruses that belong to the family Reoviridae [17] . He was successful in rescuing noncultivatable type 1 human rotavirus by gene reassortment during coinfection with a cultivatable, temperature-sensitive (ts) mutant of bovine rotavirus [17] .
Recently, refinements in tissue culture technique have made it possible to recover strains of each of the three human rotavirus serotypes directly in cell culture [18] . The scene is now set to evaluate different strains of human rotavirus for attenuation and immunogenicity in man. Manipulation of these strains to produce cold-adapted mutants may yield the desired attenuated viruses. Also, evaluation of a variety of interspecies reassortant viruses in experimental animals and in humans may shed light on the genetic determinants of virulence, allowing us to identify certain mixed constellations of animal and human rotavirus genes that render viral reassortants attenuated for man and thus suitable for use in a live attenuated rotavirus vaccine. It should also be noted that antigenic relationships between animal and human rotaviruses may allow us to use the former in prophylaxis of human disease. Several years ago we showed that prior infection of calves with a bovine rotavirus protected these animals against experimental challenge with type 2 human rotavirus [19] . Double-Stranded DNA Viruses Previously, it was shown by our group that oral administration of live type 4 adenovirus in an enteric-coated capsule produced a silent infection in the lower intestinal tract that induced effective immunity to type 4 virus [20] . This type of silent, selective, enteric adenovirus infection served as the basis for the development of a type 4, type 7 adenovirus vaccine that has effectively controlled epidemic adenovirus disease in military recruits in the U.S.A. during the past 12 years. Concern for the oncogenic potential of adenoviruses has prevented extension of this method of immunization to other adenovirus serotypes, especially those important in pediatric respiratory tract disease. Although intensive efforts to link adenoviruses to human cancer have failed to establish an association, concern for possible oncogenicity lingers on. Perhaps DNA surgery can be combined with enteric vaccination to yield an effective vaccine that will gain acceptance for use in children.
The genes of type 5 adenovirus responsible for cell transformation reside in the left-hand 8 percent of the viral genome. Using a restriction enzyme that cuts at a site 4 percent from the left-hand end of the viral genome, Jones and Shenk selected spontaneous deletion mutants lacking this site and often flanking sequences as well [10] . Some of these deletion mutants exhibited the following properties desirable for a vaccine virus: (1) viability, (2) restriction of replicative capacity in human cells, and (3) inability to transform cells in culture. These observations suggest that it should be possible to derive other mutants with a deletion in the transformation region that renders the affected viruses transformation-defective and restricted in their growth in human cells. The degree of growth restriction represents a critical property because the desired mutants must still be sufficiently competent to infect enough cells in vivo to stimulate immunity.
